parkinson's disease retatrutide clinical trial

parkinson's disease retatrutide clinical trial drug therapies in the pipeline: 2023 update retatrutide parkinson's clinical trial ly3437943

Name: parkinson's disease retatrutide clinical trial drug therapies in the pipeline: 2023 update retatrutide parkinson's clinical trial ly3437943
Brand: strongerfitness.mx
SKU: 31171767526
Price: 20.61 USD
Availability: InStock
Rating: 4.3177 (7 reviews)

SKU: 31171767526

4.3

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Sep 23 - Sep 28

Description

However, this outcome fell short of the anticipated 25% weight reduction, potentially limiting its competitive edge against Eli Lillys ZEPBOUND, which reported up to 20.9% weight loss in the SURMOUNT-1 trial. In the subsequent REDEFINE 2 trial, which focused on adults with obesity or overweight and type 2 diabetes, CagriSema achieved a 15.7% mean weight loss after 68 weeks, compared to 3.1% with placebo